OrganiGram (OGI) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
17 Dec, 2025Executive summary
Achieved record gross and net revenue, adjusted EBITDA, and international sales in fiscal 2025, maintaining #1 Canadian recreational market share at 11.9% and strong brand performance nationally.
Motif Labs and Collective Project acquisitions expanded extraction, beverage, and U.S. market presence, with significant operational synergies realized and no market share dilution.
Expanded international business with record sales in Germany, UK, Australia, and the U.S., and formalized an international business unit.
Advanced operational scale and innovation with FASTTM technology, genomics R&D, and seed-based cultivation, supporting future growth.
Launched new products and prepared for further launches in vapes, pre-rolls, and beverages, focusing on margin improvement and operational optimization.
Financial highlights
Fiscal 2025 gross revenue rose 63% year-over-year to $403.0M; net revenue up 62% to $259.2M; Q4 net revenue was $80.1M, up 79% year-over-year.
International sales reached $26.3M for fiscal 2025, up 173% year-over-year.
Adjusted gross profit for Q4 increased 85% to $30.6M; full-year adjusted gross margin was 35%, with Q4 margin at 38%.
Adjusted EBITDA for Q4 was $9.8M, up 68%–72% sequentially; full-year adjusted EBITDA was $21.9M, up 160% year-over-year.
Fiscal 2025 net loss decreased 46% to $24.8M, despite a Q4 net loss of $38M due to non-cash mark-to-market adjustments.
Cash and short-term investments at year-end totaled $84.4M, with no material debt.
Outlook and guidance
Fiscal 2026 net revenue expected to exceed $300M, with further improvements in adjusted gross margin and EBITDA, and positive free cash flow anticipated.
Capital expenditures projected below $10M, down from $17M in fiscal 2025.
Anticipate continued strong international growth, especially in vapes, pre-rolls, and new product categories, supported by innovation and EU-GMP certification.
Gross margin expected to approach 40% in fiscal 2026, driven by operational improvements and Motif synergies.
Latest events from OrganiGram
- Q1 net revenue up 49%, EBITDA up 273%, with strong margins and global expansion amid regulatory risks.OGI
Q1 202610 Feb 2026 - Returned to profitability with 25% revenue growth and expanded global footprint.OGI
Q3 20241 Feb 2026 - Motif deal, revenue gains, and innovation drive market leadership and growth outlook.OGI
Q4 202411 Jan 2026 - Record revenue, strong global expansion, and innovation drive leadership in cannabis.OGI
Investor Presentation16 Dec 2025 - Net revenue up 17% and Motif acquisition drive market leadership and global expansion.OGI
Q1 20252 Dec 2025 - Market leader drives growth through innovation, efficiency, and global expansion.OGI
Status Update29 Nov 2025 - Record revenue, margin gains, and global expansion drive strong Q2 performance.OGI
Q2 202526 Nov 2025 - Record Q3 revenue, global expansion, and positive free cash flow highlight strong performance.OGI
Q3 202523 Nov 2025